Management of pregnancy after stillbirth.
It is difficult for clinicians to counsel, evaluate, and manage subsequent pregnancies after stillbirth as little is known about pregnancy outcome after a stillbirth. In a significant number of cases, either the evaluation was incomplete or the prior stillbirth remains unexplained despite a complete work-up. In addition, there are important psychological and emotional issues when dealing with a pregnancy resulting in a stillbirth. The overall recurrence risk for stillbirth is increased 2 to 10 folds in the next pregnancy, depending on the circumstances. Understanding the circumstances of the previous stillbirth is important for counseling about stillbirth recurrence risk. Categorization of the cause of the previous stillbirth will allow better estimation of individual recurrence risk of the condition that is associated with stillbirth and help guide management.
Reddy
Uma M
UM
Pregnancy and Perinatology Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA. reddyu@mail.nih.gov
D001241:Aspirin / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood; D005260:Female; D047109:Fetal Development; D006801:Humans; D048208:Nuchal Translucency Measurement; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011247:Pregnancy; D011266:Pregnancy-Associated Plasma Protein-A / Q000032:analysis; D011295:Prenatal Care; D055502:Secondary Prevention; D050497:Stillbirth; D055988:Uterine Artery / Q000000981:diagnostic imaging; D000509:alpha-Fetoproteins / Q000032:analysis
D015415:Biomarkers; D018997:Chorionic Gonadotropin, beta Subunit, Human; D010975:Platelet Aggregation Inhibitors; D000509:alpha-Fetoproteins; D011266:Pregnancy-Associated Plasma Protein-A; D001241:Aspirin